2nd Quarter - Report
W STRATEGIES, LLC for BIOGEN
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
March 2016 CMS proposed rule implementing a new Part B drug payment model. H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Education about the value of innovative new medicines. FY 2017 Labor/HHS appropriations bill as it relates to funding for newborn screening. H.R. 6: 21st Century Cures Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.